Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Intelsius Enhances Patient Safety Products

Published: Thursday, February 13, 2014
Last Updated: Wednesday, February 12, 2014
Bookmark and Share
Company announces enhancement to ThermoTrek™ range of solutions.

Intelsius has announced an enhancement to its ThermoTrek™ range of solutions. They now feature ThermoCline Technology™ (TCT) allowing 48 plus hours of protection for temperature sensitive payloads. The TCT addition allows for simple conditioning of a single component making it easy for patients to use correctly.

ThermoTrek systems are a range of insulated, patient carry cases designed for movement of temperature sensitive medications (2-8 degrees C) either being tested in clinical trials or for approved and marketed medicines used by patients.

“Pharmaceutical companies make enormous investments in their IMPs during clinical trials and the ThermoTrek TCT systems will help patients comply with temperature sensitivity requirements and provide more reliable clinical data outcomes,” said Steve Healy, Intelsius Global Sales Director.

In commercially available temperature sensitive medicines, the system protects the patient’s investment in treatment while ensuring efficacy of the medicine.

The optional Thermochromic label on the TCT panel visually indicates and verifies the readiness for use.

“Keeping patients safe is the primary reason for the ThermoTrek TCT line of products and simplified conditioning makes it extremely easy for them to use,” said Healy. “In addition, we’ve already had great feedback from leading Pharma companies who are shipping high value biologics direct to pharmacies here in Europe.”

Every ThermoTrek TCT solution is constructed with high performance materials which give a strong resistance to tears or abrasions while offering stain and water resistance for many months of reliable use.

Each case is ergonomically designed to have a minimum impact on the patient’s daily life and enable comfortable transportation of medicine. In addition, its discreet design keeps the contents confidential.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!